John McGlynn is a Senior Scientist in Sterile Drug Product Commercialization, a part of the Merck Manufacturing Division at Merck & Co., Inc.. In this role, he supports process development and tech transfer for Merck’s phase 2/3 vaccine and biologics drug products from through filing and initial commercial launch. Prior to joining Merck, John was a graduate student at Lehigh University in Professor Kelly Schultz’s lab. John’s graduate work focused on rheological characterization of hydrogels with embedded stem cells with applications in wound healing and tissue regeneration. John holds a Ph. D. from Lehigh University and a Bachelor of Science from The Pennsylvania State University, both in Chemical Engineering.